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Abstract
Background: In recent years, a battery-powered bone marrow biopsy system was developed and cleared by the
U.S. Food and Drug Administration to allow health care providers to access the bone marrow space quickly and
efficiently. A multicenter randomized clinical trial was designed for adult patients to determine if the powered
device had advantages over traditional manually-inserted needles in regard to length of procedure, patient pain,
complications, user satisfaction, and pathological analysis of the specimens.
Methods: Adult patients requiring marrow sampling procedures were randomized for a Manual or Powered
device. Visual Analog Scale (VAS) pain scores were captured immediately following the procedure and 1 and
7 days later. Procedure time was measured and core specimens were submitted to pathology for grading.
Results: Ten sites enrolled 102 patients into the study (Powered, n = 52; Manual, n = 50). Mean VAS scores for
overall procedural pain were not significantly different between the arms (3.8 ± 2.8 for Powered, 3.5 ± 2.3 for
Manual [p = 0.623]). A day later, more patients who underwent the Powered procedure were pain-free (67%) than
those patients in the Manual group (33%; p = 0.003). One week later, there was no difference (83% for Powered
patients; 76% for Manual patients.) Mean procedure time was 102.1 ± 86.4 seconds for the Powered group and
203.1 ± 149.5 seconds for the Manual group (p < 0.001). Pathology assessment was similar in specimen quality, but
there was a significant difference in the specimen volume between the devices (Powered: 36.8 ± 21.2 mm
3;
Manual: 20.4 ± 9.0 mm
3; p = 0.039). Two non-serious complications were experienced during Powered procedures
(4%); but none during Manual procedures (p = 0.495).
Conclusions: The results of this first trial provide evidence that the Powered device delivers larger-volume bone
marrow specimens for pathology evaluation. In addition, bone marrow specimens were secured more rapidly and
subjects experienced less intermediate term pain when the Powered device was employed. Further study is
needed to determine if clinicians more experienced with the Powered device will be able to use it in a manner
that significantly reduces needle insertion pain; and to compare a larger sample of pathology specimens obtained
using the Powered device to those obtained using traditional manual biopsy needles.
Background
Bone marrow evaluation is often essential to determine
the efficacy of treatment in hematological disorders and
to monitor the recovery process in patients undergoing
bone marrow transplantation or marrow-ablative che-
motherapy [1,2]. It is also an essential component of the
staging process for patients newly diagnosed with lym-
phoproliferative diseases and certain non-hematopoietic
malignancies. Bone marrow examination is instrumental
in determining the extent of marrow damage among
patients exposed to radiatio n ,d r u g s ,c h e m i c a l s ,a n d
other myelotoxic agents [3].
Since the introduction of the Jamshidi needle in 1971,
there has been no substantial advancement in marrow
sampling technology [4]. Biopsy procedures facilitated
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but the devices were prototypes and were never com-
mercially available [5,6]. In recent years, a battery-
powered bone marrow biopsy system was developed and
cleared by the U.S. Food and Drug Administration to
allow health care providers to access the bone marrow
space quickly and efficiently. The OnControl powered
device (Vidacare Corporation, Shavano Park, TX) was
introduced for bone marrow aspirates in 2007. An
improved design featuring an integrated sterile tray
needed for core biopsies was introduced for this study
in 2009 and made available for commercial sales in
2010. The device utilizes a battery-powered drill to
insert the bone marrow needle into the iliac bone of
adult patients with minimal operator exertion. An eva-
luation of the first generation device by Cohen and
Gore indicated that the device was safe, as well as faster
and easier to use than the traditional manual procedure
[3]. The current generation of the device was also
assessed in a non-controlled evaluation with similar
results [7].
Patients with hematological disorders may require one
or more bone marrow sampling procedures during their
treatment process. Patients with cancer often suffer with
more procedural pain than those with other disorders
[8]. However, there are relatively few studies in the
recent clinical literature that address the issue of pain
management during the bone marrow sampling proce-
dure. In a 2004 study of 263 patients undergoing bone
marrow procedures, Kuball et al found that the duration
of the procedure (typically 7 minutes) was the sole inde-
pendent factor for patients’ pain intensity [9]. Antmen
et al reported VAS pain scores ranging from 1.8 to 3.5,
in an 80-patient study of children receiving bone mar-
row procedures under sedation, depending on the agent
used for sedation [10]. In a 2007 study by von Gunten
and Soskinks, technicians rated their perception of
patient pain during the bone marrow procedure. The
investigators found that the perceived pain scores corre-
lated with the difficulty of performing the procedure
[11]. The results from both of these studies suggest that
procedural difficulties cause longer procedures, resulting
in increased pain for the patient. In a 2009 study com-
paring biopsy pain when using standard Lidocaine and
buffered Lidocaine, Ruegg et al reported mean biopsy
needle insertion pain to be 38.5 (on a scale of 0-100,
with higher scores indicating more pain) when patients
were anesthetized with buffered Lidocaine. In a study
involving 235 patients conducted by Liden et al in 2009,
70% of the patients reported pain during and after bone
marrow biopsy procedures. At 1, 3, 6 and 7 days follow-
ing the bone marrow procedure, pain was present in
137 (64%), 90 (42%), 43 (20%) and 25 (12%) patients,
respectively [12].
Some providers elect to use conscious sedation during
the bone marrow procedures in an attempt to mitigate
procedural pain and discomfort; but this takes longer
and may expose the patient to additional physical risks,
result in increased liability for the provider, and require
increased patient monitoring during and after the proce-
dure [13]. In a study of 138 patients evaluating the
effects of lorazepam on pain during bone marrow proce-
dures, Park et al reported mean VAS scores during the
bone marrow procedures as 6.0 ± 2.5 for lorazepam vs.
6.2 ± 2.3 for placebo [14]. Each of those patients also
received a local injection of 1% Lidocaine. In 2010,
Degen et al conducted survey of 412 patients that
assessed pain during the bone marrow sampling proce-
dure. In this study, 336 patients received opioids or ben-
zodiazepines prior to the procedure. Medication-related
complications occurred in 32.7% of patients, with the
most frequent complications being tiredness (22.6%),
dizziness (5.7%), and nausea (4.5%) [15].
Until now no data has been available that compares
patient outcomes between Powered and Manual bone
marrow sampling devices. We report the results of this
first randomized controlled study conducted comparing
the Powered bone marrow sampling system to tradi-
tional manual biopsy needles in regard to length of pro-
cedure, patient pain, complications, user satisfaction,
and pathological analysis of the specimens.
Methods
This multi-center randomized, controlled trial was
approved by Western Institutional Review Board; and
the study was conducted in community-based cancer
clinics in accordance with ethical standards described in
the 1964 Declaration of Helsinki. Patients requiring a
bone marrow biopsy provided written informed consent
and were randomized to receive the procedure using
either a Powered or Manual bone marrow needle. The
Powered device was the OnControl Bone Marrow
Biopsy System (Vidacare Corporation, Shavano Park,
TX), an FDA-cleared device consisting of a powered dri-
ver and biopsy needle set. The battery-powered driver
resembles a small hand-held drill and drives a single
lumen needle set into the medullary cavity of the adult
iliac crest. The needle set consists of two parts: an outer
cannula, 11 gauge × 4 inches (102 mm) long; and a
bevel-tip inner stylet–used to penetrate the cortex of the
bone (Figure 1a). The specific Manual device varied
across study sites but was typically a Jamshidi-type bone
marrow biopsy needle, 11 gauge × 4 inch, which has a
two-piece T-handle design, a trocar-tapered stylet point
and a triple crown cannula tip (Figure 1b).
Operators were skilled in the use of the Manual
devices but had limited experience using the Powered
device. Each operator was required to use the Powered
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patients. Study patients at each site were randomized to
receive a bone marrow biopsy procedure with either the
Powered device or a Manual device. Targeting the pos-
terior iliac crest, biopsy procedures were performed in
accordance with local policy and device directions for
use. Procedure time was measured as time in seconds
from contact of the needle with the skin to needle
removal. Patients assessed pain at the end of the proce-
dure using a Visual Analog Scale (VAS), with scores
ranging from 0 to 10; higher scores indicating greater
pain. Pain was also assessed at one day and 7 days after
the biopsy procedure. Device-related complications and
adverse events were recorded. Operator and patient
satisfaction with the biopsy device were assessed on a
scale of 0 to 10, with higher scores indicating higher
satisfaction.
One biopsy specimen acquired using each device type
from each study site was submitted to a central patholo-
gist for quantitative and qualitative analysis. Core speci-
men measurements (length and width) were made after
bone marrow fixation and processing. The general qual-
ity of the bone biopsy was examined after processing.
After hematoxylin and eosin staining, microscopic slides
were assessed for fragmentation, crush artifact, hemor-
rhage, trabecular distortion, cell viability and other arti-
facts, and scored for quality on a scale of 1 to 4, with 4
indicating excellent.
The quality of the medullary component of the biopsy
was assessed separately to determine if sufficient medul-
lary marrow was present to evaluate the cells in the
marrow and graded on a scale of 0 to 4, with 4 indicat-
ing excellent. The overall quality of the biopsy was
assessed as to whether the sample was adequate, subop-
timal but helpful, or inadequate for a diagnosis.
After the interim analysis, the protocol was amended
to include recording the patient’s pain level immediately
following bone cortical penetration by the biopsy needle.
Patient satisfaction with the device was also assessed on
a scale of 0 to 10, with higher scores indicating higher
satisfaction. These additional data points were recorded
only after obtaining IRB approval for the protocol
revision. At the time of the protocol revision, only 28 of
the 102 enrolled patients remained for accrual into that
portion of the study.
Patients’ demographics were evaluated to determine
balance across the two study arms in terms of age, sex,
number of prior bone marrow aspirations, and amount
of pain on previous bone marrow aspiration. Statistical
tests were conducted using SAS 9.2 (SAS Institute Inc.,
Cary, NC) and IBM SPSS Statistics 19.0 (SPSS, Inc.
Chicago, IL). Continuous parameters were summarized
and compared between groups using a 2-sample t-test.
Categorical parameters were summarized as proportions
and compared using Fisher’s Exact test. A priori signifi-
cance level was set at 0.05.
Results
Thirteen device operators from 10 sites participated in
the study. All patients who completed the randomiza-
tion process (102 total; Powered, n = 52; Manual, n =
50) received the bone marrow sampling procedure. The
mean age of participating patients was 66.3 ± 14.1 years
and 56% were male. The mean height of the patients
was 169.0 ± 10.2 cm and the mean weight was 76.3 ±
16.7 kg. There were no significant differences in the
means for these variables across the two arms of the
study. Forty-four percent of the patients had hematolo-
gical disorders. See Table 1. This was the first bone
marrow biopsy for 69% of Powered and 56% of Manual
patients.
Mean VAS scores for overall procedural pain were
not significantly different between the arms (3.8 ± 2.8
for Powered and 3.5 ± 2.3 for Manual [p = 0.623]).
Assessment of needle insertion pain was done on the
last 28 patients enrolled in the study. VAS pain scores
were not different between the arms (3.1 ± 3.1 for
Powered [n = 14] and 3.2 ± 2.9 for Manual [n = 14]).
One day after the procedure, more patients who
1a  1b 
Figure 1 Figures 1a and 1b. Power driver and biopsy needle
components of the OnControl powered bone marrow sampling
system, and typical Jamshidi-type manual bone marrow biopsy
needle.
Table 1 Patient demographics by device type
Variable Manual Powered p-value
Male/female (%) 60.0/40.0 51.9/48.1 0.432
Mean age (years) 66.4 ± 13.4 66.2 ± 14.7 0.952
Mean height (cm) 169.9 ± 10.8 168.0 ± 9.5 0.355
Mean weight (kg) 78.1 ± 16.5 74.7 ± 16.9 0.312
Mean body mass index 26.9 ± 4.4 26.4 ± 5.4 0.588
Frequency of disease categories 0.135
Lymphoma 12 14
Leukemia 13 12
Multiple myeloma 10 8
Hematological 0 6
Leukemia/lymphoma 2 0
Other 13 12
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(67%) than those patients in the Manual group (33%;
p = 0.003). One week following the procedure, there
was no difference in the proportion of patients who
were pain-free (83% for Powered patients; 76% for
Manual patients). Notably, mean procedure time was
shorter for the Powered group (102.1 ± 86.4 seconds)
than for the Manual group (203.1 ± 149.5 seconds; p <
0.001). Biopsy core acquisition success rate was similar
between the arms (Powered: 90.4%; Manual: 98.0%; p =
0.205). Assessment by pathology showed equivalence
in core specimen quality parameters and length and
width, but the specimen volume was larger in the
Powered group (36.8 mm
3 ± 21.2) than the Manual
group (20.4 mm
3 ±9 . 0 ;p = 0.039). There was no differ-
ence between the two devices for operator satisfaction,
nor for patient satisfaction. There were two non-serious
complications for the Powered (3.8%). In one case, the
patient’s skin became wrapped around the shaft of the
rotating biopsy needle; and in the other case, the clini-
cian’s glove became wrapped for a very brief time
around the rotating biopsy needle. There were no
complications for the Manual procedure (p = 0.495).
See Table 2.
Discussion
We propose that a major advantage of the Powered
system is that it allows clinicians to more quickly
complete the bone marrow sampling procedure. In our
study, the mean time from needle to skin contact to
removal of the needle using the Powered system was
approximately half the time required using the Manual
device 102.1 ± 86.4 seconds vs. 203.1 ± 149.5 seconds,
respectively). Patients undergoing bone marrow biopsy
procedures most likely expect some level of pain. Most
patients are willing to undergo the procedure and a rea-
s o n a b l el e v e lo fp a i n ,p r o v i d i n gt h ep r o c e d u r et i m ei s
relatively short. Assuming the validity of Kuball et al’s
finding that procedure time has the greatest impact on
pain, use of the Powered system could have a positive
effect on many patients’ perception of the bone marrow
procedure in general.
Another important finding from our study is that
whereas patients generally expect pain during any inva-
sive procedure, they may not expect or tolerate persis-
tent residual pain afterwards. In our study, 67% of the
patients who received the bone marrow biopsy proce-
dure using the Powered device were pain-free within 24
hours compared to only 33% of patients who received
the procedure with the Manual device, a statistically and
clinically significant finding. In the Liden et al study
using the Manual procedure, only 36% of patients were
without pain after 24 hours, very similar to the results
in the Manual group in our study [12].
As expected, there were few complications in our
study with either the Powered or Manual bone marrow
biopsy procedures. The two observed complications
occurred with a single operator’s use of the Powered
device. In one case, a small portion of the patient’ss k i n
wrapped around the rotating needle. This could have
been avoided by holding the skin tautly at the needle
insertion site. In the other case, the operator’sl a t e x
glove became wrapped around the rotating needle,
which could have been avoided by not placing the
gloved finger too close to the rotating needle. It is
recognized that these types of complications are poten-
tially serious and not likely to occur with manual
devices. But it is felt that complications of this type can
be avoided by emphasizing this potential problem and
methods to avoid the problem during operator training.
Moreover, considering that both these problems were
experienced by only one of 13 operators participating in
the study, their prevalence is not felt to be wide-spread.
Clinicians attempt to conduct bone marrow sampling
procedures quickly and safely with as little pain and dis-
comfort to the patient as possible; however, the ultimate
goal of the procedure is to acquire a bone marrow
Table 2 Results by device type
Device Efficacy Manual Powered p-value
Able to acquire biopsy core
specimen
98.0% 90.4% 0.205
Mean number attempts for core
acquisition
1.5 ± 0.8 1.2 ± 0.5 0.112
Mean time core acquisition
(seconds)
203.1 ±
149.5
102.1 ±
85.4
0.000*
Patient Pain Scores Manual Powered p-value
Mean VAS needle insertion (0-10) 3.2 ± 2.9 3.1 ± 3.1 0.900
Mean VAS overall (0-10) 3.5 ± 2.3 3.8 ± 2.8 0.623
Pain-free patients 24 hours post
procedure
33.3% 66.7% 0.003*
Pain-free patients 7 days post
procedure
76.1% 82.6% 0.607
Satisfaction & Complications Manual Powered p-value
Operator satisfaction (0-10) 7.8 ± 2.1 8.1 ± 1.7 0.488
Patient satisfaction (0-10) 9.3 ± 1.6 9.4 ± 1.2 0.778
Device related complications 0% 3.8% 0.495
Core Biopsy Pathology
Assessment
Manual Powered p-value
Mean length (mm) 11.0 ± 5.5 13.3 ± 6.6 0.368
Mean width (mm) 1.3 ± 0.5 1.7 ± 0.5 0.123
Mean volume (mm
3) 20.4 ± 9.0 36.8 ±
21.2
0.039*
General quality excellent/good 80.0% 66.7% 0.628
Medullary quality excellent/good 70.0% 55.6% 0.650
Overall quality rated adequate 70.0% 77.8% 1.000
*denotes statistical significance.
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Adequate specimens need to be of adequate size and
free of crush trabecular distortion and other artifact.
Inadequate specimens can diminish the clinician’s ability
to make an accurate diagnosis and/or assessment of the
patient’s clinical status. Bishop et al found only 42% of
bone marrow biopsy specimens were adequate for accu-
rate diagnosis in a study involving 767 patients [16]. In
the current study, there were no differences between the
two procedure types in specimen quality or length; how-
ever, use of the Powered device resulted in bone marrow
core specimens that had 80% more volume than speci-
mens obtained with the Manual device. Although length
is generally the criteria used for determining the ideal
size of a bone marrow core specimen, specimen volume
m a yb eam o r er e l e v a n ti n d i c a t o ro ft h ea m o u n to ft i s -
sue available for analysis. Larger tissue volume of the
specimen may increase the ability of the pathologist to
conduct a thorough analysis and identify focal lesions.
The cost of using the Powered device must be consid-
ered in decisions regarding its use in the clinic. While
the powered driver can be used up to 500 times, the
needle and other components are for single use and
part of a tray that generally costs $60 to $70 more than
the Manual device. Although needle-for-needle, the cost
of the Powered system is higher, the total cost for the
disposable needle tray is covered by insurance reimbur-
sement under most plans. While the seemingly high
cost of the Powered device might negatively influence a
decision to adopt its use, the concerns of most clinicians
and patients are not simply the costs of the material and
equipment required to do the procedure but the costs of
these items together with their quality and patient out-
come. Our study and other recent studies [17,18], sug-
gest that the Powered system enables clinicians to
consistently obtain biopsy specimens of superior size
and quality than those obtained using the Manual nee-
dles. In many cases, the lower cost of the Manual device
may be offset by the necessity to repeat the procedure–
requiring more materials and clinician time. Regardless
of costs, we feel using the Powered system adds value to
the process in terms of speed, efficiency, and patient
comfort.
There were several limitations in this study. As with
any new device, there is a learning curve that must be
negotiated before operators can gain proficiency. While
our study protocol stipulated that the operator complete
3 to 5 Powered device uses in non-study subjects before
performing the procedure on study patients, in hindsight
perhaps those numbers should have been higher.
Another limitation was initially capturing patient pain
scores as an “overall” event that included the aspiration
portion of the bone marrow sampling procedure. Gener-
ally, bone marrow aspiration is painful regardless of the
needle-type used to withdraw the liquid bone marrow
specimen. This extreme pain during the aspiration
phase may obscure any differentiation in pain levels
between the two device types during the less painful
phases of the procedure. This phenomenon was realized
after the interim analysis. By the time the study protocol
could be revised to include recording needle insertion
pain, patient accrual was 72% complete. Thus, we were
unfortunately able to collect very little data specifically
on needle insertion pain. A final limitation was that
relatively few core specimens were available for pathol-
ogy analysis. Our initial plan was to conduct quality
analysis for each specimen at a central laboratory, but
some investigators were reluctant to send specimens to
the central laboratory following analysis at their local
laboratory. The compromise was that two specimens
from each center were analyzed, one for each device
type.
Conclusions
The results of this first multicenter randomized
controlled trial evaluating the Powered bone marrow
biopsy system suggest that use of the Powered bone
marrow biopsy device may deliver larger-volume bone
marrow core specimens for analysis, markedly shorten
the procedure time, and reduce intermediate-term pain–
important considerations for both the medical provider
and the patient when determining how best to obtain
bone marrow specimens. Further study is needed to
determine if clinicians more experienced with the
Powered device will be able to use it in a manner that
significantly reduces needle insertion pain; and to com-
pare a larger sample of pathology specimens obtained
using the Powered device to those obtained using
traditional manual biopsy needles.
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